Spearhead Capital Advisors, LLC Neurocrine Biosciences Inc Transaction History

Spearhead Capital Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$72.45 - $94.81 $291,249 - $381,136	-4,020 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$79.65 - $106.22 $3,823 - $5,098	48 Added 1.21%	4,020 $342,000
Q3 2021 Oct 27, 2021	SELL	$86.18 - $99.03 $2,413 - $2,772	-28 Reduced 0.7%	3,972 $381,000
Q2 2021 Aug 10, 2021	BUY	$89.43 - $102.27 $53,210 - $60,850	595 Added 17.47%	4,000 $389,000
Q1 2021 Apr 28, 2021	BUY	$87.57 - $119.4 $94,312 - $128,593	1,077 Added 46.26%	3,405 $331,000
Q4 2020 Feb 02, 2021	BUY	$86.91 - $108.33 $12,341 - $15,382	142 Added 6.5%	2,328 $223,000
Q3 2020 Oct 16, 2020	BUY	$96.16 - $135.15 $13,847 - $19,461	144 Added 7.05%	2,186 $210,000
Q2 2020 Jul 16, 2020	BUY	$85.09 - $130.36 $173,753 - $266,195	2,042 New	2,042 $249,000

627

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.